Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Decline in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 153,000 shares, a decrease of 12.7% from the December 31st total of 175,300 shares. Based on an average daily trading volume, of 301,300 shares, the short-interest ratio is presently 0.5 days. Currently, 2.4% of the company’s shares are short sold.

Protagenic Therapeutics Trading Down 3.4 %

PTIX stock opened at $0.37 on Monday. The business’s fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.60. Protagenic Therapeutics has a twelve month low of $0.36 and a twelve month high of $1.87.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.